Nothing Special   »   [go: up one dir, main page]

IL134917A - Processes for preparing hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof - Google Patents

Processes for preparing hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof

Info

Publication number
IL134917A
IL134917A IL13491795A IL13491795A IL134917A IL 134917 A IL134917 A IL 134917A IL 13491795 A IL13491795 A IL 13491795A IL 13491795 A IL13491795 A IL 13491795A IL 134917 A IL134917 A IL 134917A
Authority
IL
Israel
Prior art keywords
hydroxydiphenylmethyl
water
piperidinyl
hydroxybutyl
minutes
Prior art date
Application number
IL13491795A
Other languages
English (en)
Original Assignee
Marion Merrell Dow Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26937420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL134917(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Marion Merrell Dow Inc filed Critical Marion Merrell Dow Inc
Publication of IL134917A publication Critical patent/IL134917A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL13491795A 1994-05-18 1995-05-16 Processes for preparing hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof IL134917A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24573194A 1994-05-18 1994-05-18
US41716195A 1995-04-11 1995-04-11
IL11374795A IL113747A (en) 1994-05-18 1995-05-16 Processes for preparing anhydrous forms of antihistaminic piperidine derivatives, polymorphs and psedomorphs thereof

Publications (1)

Publication Number Publication Date
IL134917A true IL134917A (en) 2001-07-24

Family

ID=26937420

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13491795A IL134917A (en) 1994-05-18 1995-05-16 Processes for preparing hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
IL11374795A IL113747A (en) 1994-05-18 1995-05-16 Processes for preparing anhydrous forms of antihistaminic piperidine derivatives, polymorphs and psedomorphs thereof
IL13491700A IL134917A0 (en) 1994-05-18 2000-03-07 Processes for preparing hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL11374795A IL113747A (en) 1994-05-18 1995-05-16 Processes for preparing anhydrous forms of antihistaminic piperidine derivatives, polymorphs and psedomorphs thereof
IL13491700A IL134917A0 (en) 1994-05-18 2000-03-07 Processes for preparing hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof

Country Status (18)

Country Link
US (12) US20010014741A1 (xx)
EP (3) EP1178041A1 (xx)
JP (7) JPH10500134A (xx)
CN (3) CN1907967B (xx)
AT (1) ATE220667T1 (xx)
AU (1) AU693892B2 (xx)
CA (3) CA2449419C (xx)
DE (1) DE69527429T2 (xx)
DK (1) DK0766668T3 (xx)
ES (1) ES2176329T3 (xx)
FI (1) FI964565A (xx)
HK (2) HK1098467A1 (xx)
HU (1) HU227676B1 (xx)
IL (3) IL134917A (xx)
MX (1) MX9605613A (xx)
NO (1) NO315319B1 (xx)
PT (1) PT766668E (xx)
WO (1) WO1995031437A1 (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135571B2 (en) 1994-05-18 2006-11-14 Aventis Pharmaceuticals, Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9400555D0 (en) * 1994-01-13 1994-03-09 Short Brothers Plc Boundery layer control in aerodynamic low drag structures
MX9706449A (es) * 1995-02-28 1997-11-29 Hoechst Marion Roussel Inc Composicion farmaceutica para compuestos de piperidinalcanol.
WO1999009957A1 (en) * 1997-08-26 1999-03-04 Hoechst Marion Roussel, Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
IN191492B (xx) * 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
US6613906B1 (en) * 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
CH695216A5 (de) * 2001-02-23 2006-01-31 Cilag Ag Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes.
AU2002305162A1 (en) * 2001-04-09 2002-10-21 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
EE200400010A (et) * 2001-06-18 2004-02-16 Dr. Reddy's Laboratories Ltd. 4-[4-[4-(hüdroksüdifenüülmetüül)-1-piperidinüül]-1-hüdroksübutüül]-a,a-dimetüülben seenäädikhappe ja selle hüdrokloriidi uued kristalsed vormid
ES2301662T3 (es) * 2001-07-31 2008-07-01 Texcontor Etablissement Polimorfo de clorhidrato de fexofenadina.
US20030158227A1 (en) * 2001-11-08 2003-08-21 Barnaba Krochmal Polymorphs of fexofenadine base
JP2005532356A (ja) * 2002-06-10 2005-10-27 テバ ファーマシューティカル インダストリーズ リミティド 塩酸フェキソフェナジンの多型体ｘｖｉ
JP3910907B2 (ja) * 2002-10-29 2007-04-25 新光電気工業株式会社 キャパシタ素子及びこの製造方法、半導体装置用基板、並びに半導体装置
ATE425170T1 (de) * 2003-07-03 2009-03-15 Teva Pharma Kristallformen der zoledronsäure und deren natrioumsalze, amorphes natriumzoledronat und verfahren zu deren herstellung
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
KR20070007196A (ko) * 2004-04-26 2007-01-12 테바 파마슈티컬 인더스트리즈 리미티드 펙소페나딘 히드로클로라이드의 결정형 및 이의 제조 방법
ITMI20041143A1 (it) 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
EP1616861A3 (en) * 2004-06-15 2006-02-08 Dipharma S.p.A. A process for the preparation of keto compounds
ITMI20041568A1 (it) * 2004-07-30 2004-10-30 Dipharma Spa "polimorfi di fexofenadina base"
JP2008514641A (ja) * 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
DOP2006000274A (es) * 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
KR20090037930A (ko) * 2006-07-11 2009-04-16 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. 조절 방출 제형
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
US20090306135A1 (en) 2008-03-24 2009-12-10 Mukesh Kumar Sharma Stable amorphous fexofenadine hydrochloride
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
CN102595879B (zh) 2009-11-06 2014-08-06 巴斯夫欧洲公司 4-羟基苯甲酸和选定农药的结晶配合物
IT1400965B1 (it) * 2010-06-15 2013-07-05 Dipharma Francis Srl Polimorfi di fexofenadina
ES2403130B1 (es) 2010-06-15 2014-09-29 Chemelectiva S.R.L. Forma polimórfica de clorhidrato de fexofenadina, compuestos intermedios y procedimiento para su preparación
US9420872B2 (en) * 2010-08-23 2016-08-23 Jason Bird Apparatus and system for holding game-calling devices
JP2012087100A (ja) * 2010-10-21 2012-05-10 Sumitomo Chemical Co Ltd 形態ｉのフェキソフェナジン一塩酸塩の製造方法
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US631375A (en) * 1899-04-12 1899-08-22 Ephraim Musselman Face-protector.
US3448152A (en) * 1966-11-03 1969-06-03 Jefferson Chem Co Inc Amine recovery
US3878217A (en) * 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
BE794598A (fr) 1972-01-28 1973-05-16 Richardson Merrell Inc Nouveaux derives olefiniques de piperidines substituees en 4 et leur procede de preparation
US3965257A (en) 1972-01-28 1976-06-22 Richardson-Merrell Inc. Compositions and methods for the treatment of the symptoms of histamine induced allergic reactions
US4254130A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4285957A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
US4285958A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4742175A (en) 1986-05-07 1988-05-03 Merrell Dow Pharmaceuticals Inc. Preparation of polymorphically pure terfenadine
JPH02213431A (ja) * 1989-02-13 1990-08-24 Kobe Steel Ltd ＳｉＣウィスカ強化Ａｌ合金複合材料
DE4034218A1 (de) 1990-10-27 1992-04-30 Merck Patent Gmbh Verfahren zur herstellung von carebastin
TW198008B (xx) 1991-04-08 1993-01-11 Green Cross Corp
CA2117892C (en) * 1992-04-10 2001-12-18 Chi-Hsin R. King 4-diphenylmethyl piperidine derivatives and process for their preparation
US5631375A (en) * 1992-04-10 1997-05-20 Merrell Pharmaceuticals, Inc. Process for piperidine derivatives
WO1993023047A1 (en) * 1992-05-11 1993-11-25 Merrell Dow Pharmaceuticals Inc. Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient
ES2284740T3 (es) 1992-08-03 2007-11-16 Sepracor Inc. Carboxilato de terfenadina y el tratamiento de la irritacion cutanea.
US5315016A (en) 1992-10-13 1994-05-24 Nycomed Dak A/S Process for preparing pure podophyllotoxin
CA2181089C (en) 1993-06-24 2000-05-23 Thomas E. D'ambra Piperidine derivatives and process for their production
ATE174589T1 (de) 1993-06-24 1999-01-15 Albany Molecular Res Inc Verfahren zur herstellung von piperidinderivaten
EP1260504A1 (en) 1993-06-25 2002-11-27 Merrell Pharmaceuticals Inc. Process for the preparation of antihistaminic 4-diphenylmethyl piperidine derivatives
US6147216A (en) 1993-06-25 2000-11-14 Merrell Pharmaceuticals Inc. Intermediates useful for the preparation of antihistaminic piperidine derivatives
EP1178041A1 (en) * 1994-05-18 2002-02-06 Aventis Pharmaceuticals Inc. Process for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives
US5576610A (en) 1994-07-05 1996-11-19 Motorola, Inc. Method and apparatus for determining battery characteristics
IL134772A (en) 1995-02-28 2002-02-10 Aventis Pharma Inc Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form
MX9706449A (es) 1995-02-28 1997-11-29 Hoechst Marion Roussel Inc Composicion farmaceutica para compuestos de piperidinalcanol.
US5574045A (en) * 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
WO1999009957A1 (en) * 1997-08-26 1999-03-04 Hoechst Marion Roussel, Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
US6214427B1 (en) * 1998-08-28 2001-04-10 General Electric Company Method of making an electronic device having a single crystal substrate formed by solid state crystal conversion
US6613906B1 (en) 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
US20020177680A1 (en) * 2000-08-23 2002-11-28 Hubbell Jeffrey A. Novel polymer compounds
US6475942B1 (en) * 2000-09-05 2002-11-05 General Electric Company Conversion of polycrystalline alumina to single crystal sapphire using molybdenum doping
AU2002305162A1 (en) * 2001-04-09 2002-10-21 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
US20090211514A1 (en) * 2008-02-26 2009-08-27 Lehigh University Single crystal conversion process

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135571B2 (en) 1994-05-18 2006-11-14 Aventis Pharmaceuticals, Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US7666881B2 (en) 1994-05-18 2010-02-23 Aventis Holdings, Inc. Methods of treating allergic reactions using hydrated forms of antihistaminic piperidine derivatives

Also Published As

Publication number Publication date
IL113747A0 (en) 1995-08-31
CN1907967A (zh) 2007-02-07
DE69527429T2 (de) 2003-03-20
US20010012896A1 (en) 2001-08-09
HU9603167D0 (en) 1997-01-28
US20080167471A1 (en) 2008-07-10
JP4503907B2 (ja) 2010-07-14
NO964859D0 (no) 1996-11-15
HK1098467A1 (en) 2007-07-20
US20010025106A1 (en) 2001-09-27
CA2585705A1 (en) 1995-11-23
CA2189007A1 (en) 1995-11-23
IL113747A (en) 2001-05-20
DK0766668T3 (da) 2002-10-28
NO315319B1 (no) 2003-08-18
CA2189007C (en) 2004-03-02
FI964565A0 (fi) 1996-11-14
CN1907967B (zh) 2012-07-04
JPH10500134A (ja) 1998-01-06
JP2002308850A (ja) 2002-10-23
US7138524B2 (en) 2006-11-21
AU693892B2 (en) 1998-07-09
US20030045721A1 (en) 2003-03-06
CN1623985A (zh) 2005-06-08
US20010014741A1 (en) 2001-08-16
US7662835B2 (en) 2010-02-16
JP2002316978A (ja) 2002-10-31
HU227676B1 (en) 2011-11-28
JP4503908B2 (ja) 2010-07-14
JP2002255935A (ja) 2002-09-11
US20020193601A1 (en) 2002-12-19
JP4503909B2 (ja) 2010-07-14
FI964565A (fi) 1996-11-14
US20080167469A1 (en) 2008-07-10
US7135571B2 (en) 2006-11-14
DE69527429D1 (de) 2002-08-22
EP1178041A1 (en) 2002-02-06
EP0766668B1 (en) 2002-07-17
MX9605613A (es) 1998-05-31
US7666881B2 (en) 2010-02-23
CA2449419A1 (en) 1995-11-23
AU2426595A (en) 1995-12-05
IL134917A0 (en) 2001-05-20
WO1995031437A1 (en) 1995-11-23
US20070021462A1 (en) 2007-01-25
US20020193603A1 (en) 2002-12-19
US20070021461A1 (en) 2007-01-25
JP2010120969A (ja) 2010-06-03
US20020193600A1 (en) 2002-12-19
HK1137742A1 (en) 2010-08-06
JP2002255936A (ja) 2002-09-11
NO964859L (no) 1996-11-15
CA2585705C (en) 2012-04-17
CN1148849A (zh) 1997-04-30
HUT76134A (en) 1997-06-30
ES2176329T3 (es) 2002-12-01
PT766668E (pt) 2002-11-29
ATE220667T1 (de) 2002-08-15
US20040014976A1 (en) 2004-01-22
CA2449419C (en) 2011-09-06
EP0766668A1 (en) 1997-04-09
EP2354125A1 (en) 2011-08-10
JP2002308849A (ja) 2002-10-23

Similar Documents

Publication Publication Date Title
EP0766668B1 (en) Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
EP0812195B1 (en) Pharmaceutical composition for piperidinoalkanol compounds
US20070129401A1 (en) Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
NZ285229A (en) 4-(biphenylmethyl)piperdine derivatives in anhydrous and hydrated forms, their preparation and medicaments thereof
IL134771A (en) Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form

Legal Events

Date Code Title Description
NP Permission for amending the patent specification granted (section 66, patents law 1967)
FF Patent granted
KB20 Patent renewed for 20 years
EXP Patent expired